case_images: PMC11059057_01
case_images: The patient's clinical course illustrated using lung computed tomography and brain magnetic resonance imaging. (A1) Baseline imaging demonstrating abnormal lung mass and pleural effusion in the right lung. (A2) After 3 weeks of only crizotinib treatment, the chest CT scan shows that the lung mass and pleural fluid did not change significantly. (A3) After crizotinib plus three cycles of bevacizumab, the lung mass shrank, the pleural fluid decreased. (A4) After crizotinib plus bevacizumab brain radiotherapy, the chest CT scan shows disease progression, and next-generation sequencing detected the resistance mutation as METp.Y1230H. (B1) Brain MRI showing brain metastasis. (B2) After 3 weeks of only crizotinib treatment, most of the lesions in the brain slightly decreased, and edema around the lesions decreased, achieving partial response (PR). (B3) After crizotinib plus three cycles of bevacizumab, the head lesions grew. CT, computed tomography; MRI, magnetic resonance imaging .
case_images: fonc-14-1370901-g001.jpg
case_images: PMC11059057_01_fonc-14-1370901-g001.jpg
case_images: f1
case_images: However, computed tomography and magnetic resonance imaging revealed a tumor in the lower lobe of her right lung with pleural effusion (Figure A1) and multi-organ metastasis, including the brain (Figure B1), vertebrae, and bone.